Nonmetal Radionuclide Or Intended Radionuclide (e.g., Carbon) Patents (Class 424/1.81)
-
Publication number: 20130315825Abstract: Derivatives of phenothiazine, phenoxazine, and phenazine compounds and their use as ?-synuclein ligands are described. Also described are methods of using these compounds and their radiolabeled analogs for the detection, monitoring, and treatment of synucleinopathies, including Parkinson's disease.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Washington UniversityInventors: Zhude Tu, Robert Mach, Lihai Yu, Paul Kotzbauer
-
Publication number: 20130302246Abstract: The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.Type: ApplicationFiled: February 7, 2013Publication date: November 14, 2013Inventor: The General Hospital Corporation
-
Patent number: 8580229Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.Type: GrantFiled: October 23, 2012Date of Patent: November 12, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: William E. Klunk, Chester A. Mathis, Jr.
-
Publication number: 20130287687Abstract: The present disclosure relates to organic chemistry and in particular to a series of corticotropin releasing factor type-1 (CRF1) receptor ligand compounds and compositions, as well as methods of preparation and treatment.Type: ApplicationFiled: April 30, 2013Publication date: October 31, 2013Inventor: EMORY UNIVERSITY
-
Patent number: 8568689Abstract: The invention relates to contrast agents for detection of the Urokinase Plasminogen Activator Receptor (uPAR). More specifically the invention relates to contrast agents comprising a peptidic vector binding to the uPAR, labelled with an imageable moiety.Type: GrantFiled: September 28, 2005Date of Patent: October 29, 2013Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bente E. Arbo
-
Publication number: 20130272959Abstract: Described is a method, and a combination of agents for used therein, by which an agent administered to a subject can be rapidly cleared from circulation. This is achieved by providing an Administration Agent (e.g. a probe for pretargeting) with a reactive group and providing a Clearing Agent with another reactive group, said reactive groups forming a bio-orthogonally reactive pair. Preferably, the reactive pair comprises a cyclooctene or cyclooctyn as one reactant, and a diene as the other reactant. The method and combination can be used for the removal of any bindable molecule from circulation, such as an excess of a pre-targeting probe in the course of a pre-targeting method, a targeting or imaging agent delivered, or the removal of any biomolecule already present in circulation.Type: ApplicationFiled: December 16, 2011Publication date: October 17, 2013Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Raffaella Rossin, Tilman Laeppchen, Sandra Martina Van Den Bosch, Marc Stefan Robillard, Ronny Mathieu Versteegen
-
Patent number: 8558003Abstract: The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4?-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof.Type: GrantFiled: August 11, 2010Date of Patent: October 15, 2013Assignee: The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
-
Publication number: 20130266513Abstract: Methods for detecting or ruling out a meningioma in a patient using a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative, and a medical imaging technique such as positron emission tomography/computed tomography are disclosed.Type: ApplicationFiled: October 11, 2011Publication date: October 10, 2013Inventors: Geoffrey B. Johnson, Val J. Lowe, Mark A. Nathan, Joseph E. Parisi
-
Patent number: 8551448Abstract: The present invention provides rotenone analogs and methods of making and using them. Labeled with single photon and positron emitting isotopes, the rotenone analogs of the present invention are useful in, for example, clinical imaging applications as tracers to measure cardiac blood flow and detect regions of ischemia.Type: GrantFiled: November 18, 2008Date of Patent: October 8, 2013Assignee: The Regents of the University of CaliforniaInventors: Henry F. VanBrocklin, James P. O'Neil, Andrew R. Gibbs, Nandanan Erathodiyil
-
Publication number: 20130259805Abstract: The invention provides compounds and a method for imaging aggregated ?-synuclein, e.g., Lewy bodies or Lewy neurites, in a tissue or organ.Type: ApplicationFiled: November 11, 2011Publication date: October 3, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: Brian Bacskai
-
Patent number: 8546417Abstract: The invention relates to fused and spirocycle compounds of Formula I: or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.Type: GrantFiled: June 1, 2012Date of Patent: October 1, 2013Assignee: Purdue Pharma L.P.Inventors: Zhengming Chen, Laykea Tafesse
-
Patent number: 8545809Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.Type: GrantFiled: December 12, 2011Date of Patent: October 1, 2013Assignee: Immunomedics, Inc.Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
-
Patent number: 8540968Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.Type: GrantFiled: December 20, 2005Date of Patent: September 24, 2013Assignee: Cellectar, Inc.Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk
-
Patent number: 8535641Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.Type: GrantFiled: March 2, 2005Date of Patent: September 17, 2013Assignee: Cellectar, Inc.Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk
-
Publication number: 20130230459Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.Type: ApplicationFiled: November 8, 2011Publication date: September 5, 2013Applicant: Janssen Pharmaceuticals, Inc.Inventors: José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen, Michel Koole
-
Patent number: 8524193Abstract: The invention provides lipophilic salts, particularly, lipophilic salts comprising a pharmaceutically acceptable anion and at least one phosphonium or ammonium cation. In certain embodiments, the cation is labeled with one or more radioisotopes. The lipophilic salts of the invention exhibit an affinity for dysfunctional mitochondria, and are useful for the imaging of cardiovascular diseases and disorders. The invention also provides pharmaceutical compositions and methods of using the lipophilic salts.Type: GrantFiled: February 6, 2003Date of Patent: September 3, 2013Assignee: The Johns Hopkins UniversityInventors: Igal Madar, Hayden T. Ravert, Robert Francis Dannals, Ursula A. Scheffel, James J. Frost
-
Patent number: 8518371Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.Type: GrantFiled: November 29, 2010Date of Patent: August 27, 2013Assignee: Natural Pharmacia International, Inc.Inventors: David Y-W Lee, Xiao-Shen Ji, James A. Raleigh
-
Patent number: 8512676Abstract: The methods described herein are based on the observation that oscillations in breath isotope ratio data can be used for the purpose of identifying an “unhealthy” state in an organism such as a human. Described herein are methods of determining the state of health of an individual, such as the transition from healthy to infected, by identifying changes in oscillation modes in breath isotope ratio data. Changes in the frequency and/or amplitude of the oscillation modes are correlated with the heath of the individual. The methods can advantageously be used to provide information about the health of an individual in shorter periods of time than previous methods.Type: GrantFiled: March 7, 2012Date of Patent: August 20, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hamid R. Eghbalnia, Mark E. Cook, Warren Paul Porter, Daniel Elmer Butz
-
Publication number: 20130209360Abstract: The present disclosure provides compositions for in vivo imaging of hydrogen peroxide; and methods for detecting hydrogen peroxide in vivo. The compositions and methods find use in various diagnostic applications, which are also provided.Type: ApplicationFiled: August 22, 2011Publication date: August 15, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Christopher J. Chang, Alexander R. Lippert
-
Patent number: 8506932Abstract: The present invention provides novel tetracyclic indole compounds of Formula (I) either as in vivo imaging agents or as therapeutic agents. A method for the preparation of the in vivo imaging agent compound is also provided by the invention, as well as a precursor for use in said method. Pharmaceutical compositions comprising the compounds of the invention are additionally provided. Where the pharmaceutical composition comprises a compound suitable for in vivo imaging, a kit is provided for the preparation of the pharmaceutical composition. In a further aspect, use of the compound for in vivo imaging or treatment of conditions associated with PBR is provided.Type: GrantFiled: November 20, 2006Date of Patent: August 13, 2013Assignee: Hammersmith Imanet LimitedInventors: Erik Arstad, Ian Wilson, Sajinder Kaur Luthra, Frank Brady, Bengt Langstrom, Farhad Karimi, Edward George Robins, Bo Shan
-
Patent number: 8506928Abstract: The present invention relates to peptides which home to cells, e.g. heart cells, with high selectivity and which can be useful in the form of compositions. Such compositions can be used, e.g., for selectively targeting a systemically administered therapeutic agent or imaging agent to a cell or tissue in a subject. The present invention further relates to methods of using the compositions for imaging, e.g. PET imaging, and targeting cells, e.g. for delivering a therapeutic agent to one or more target cells in a subject.Type: GrantFiled: September 8, 2008Date of Patent: August 13, 2013Assignee: The Regents of the University of CaliforniaInventors: Katherine Ferrara, Hua Zhang, Jiro Kusunose
-
Patent number: 8501152Abstract: The present invention relates to a method of radiolabelling carbon nanotubes, to the radiolabelled carbon nanotubes that can be obtained by implementing this method, and to applications thereof.Type: GrantFiled: November 6, 2008Date of Patent: August 6, 2013Assignee: Commissariat a l'Energie Atomique et aux Energies AlternativesInventors: Frëdëric Taran, Dominique Georgin
-
Patent number: 8496912Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: GrantFiled: January 29, 2013Date of Patent: July 30, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Patent number: 8491869Abstract: Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and ?-amyloid peptides are presented herein. The invention also relates to methods of imaging A? and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.Type: GrantFiled: March 23, 2010Date of Patent: July 23, 2013Assignee: Eli Lilly and CompanyInventors: Umesh B. Gangadharmath, Hartmuth C. Kolb, Peter J. H. Scott, Joseph C. Walsh, Wei Zhang, Anna Katrin Szardenings, Anjana Sinha, Gang Chen, Eric Wang, Vani P. Mocharia, Chul Yu, Changhui Liu, Daniel Kurt Cashion, Dhanalakshmi Kasi
-
Publication number: 20130183239Abstract: Novel choline-derived radiotracer (s) having an isotopic carbon for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal, ovarian, endometrial, lung and prostate cancer—primary tumor, nodal disease or metastases).Type: ApplicationFiled: September 20, 2011Publication date: July 18, 2013Applicants: IMPERIAL COLLEGE, GE HEALTHCARE LIMITEDInventors: Eric Ofori Aboagye, Edward George Robins, Graham Smith, Sajinder Luthra
-
Patent number: 8486372Abstract: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: GrantFiled: May 23, 2011Date of Patent: July 16, 2013Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Gang Chen, Qianwa Liang, Tieming Zhao
-
Publication number: 20130164218Abstract: This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein.Type: ApplicationFiled: December 27, 2012Publication date: June 27, 2013Applicant: EMORY UNIVERSITYInventor: EMORY UNIVERSITY
-
Publication number: 20130164217Abstract: Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders.Type: ApplicationFiled: December 20, 2012Publication date: June 27, 2013Applicant: Meso Scale Technologies, LLCInventors: Robert M. Umek, Pankaj Oberoi
-
Patent number: 8470297Abstract: This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.Type: GrantFiled: September 10, 2010Date of Patent: June 25, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Brian DerHua Lu, Siu-Long Yao, Cynthia Seidel-Dugan, Yan Wang
-
Publication number: 20130156700Abstract: A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the compound includes at least one C11 or F18 label thereon; allowing the compound to penetrate into the tissue of the subject; and collecting a PET image of the CNS or brain tissue of the subjectType: ApplicationFiled: November 28, 2012Publication date: June 20, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Publication number: 20130156699Abstract: The present invention relates to Radiolabeled Compounds labeled with fluorine, bromine, iodine, carbon, or tritium isotopes and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.Type: ApplicationFiled: November 5, 2012Publication date: June 20, 2013Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Joseph John MANN, J.S. Dileep KUMAR
-
Publication number: 20130149239Abstract: The present invention relates to novel 5-pyrrolidinylsulfonyl isatin derivatives, non-peptidyl Caspase binding Radioligands (CbRs) and CbR-transporter conjugates derived from said isatin derivatives, diagnostic compositions comprising said compounds of the invention and their use for non-invasive diagnostic imaging.Type: ApplicationFiled: November 26, 2012Publication date: June 13, 2013Applicant: Universitatsklinikum MunsterInventor: Universitatsklinikum Munster
-
Patent number: 8444956Abstract: The present application discloses compositions and methods of synthesis and use of 68Ga, 18F or 19F labeled molecules of use in PET or MRI imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a chelating moiety, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 68Ga, 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. In more preferred embodiments, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment.Type: GrantFiled: May 17, 2012Date of Patent: May 21, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Patent number: 8435490Abstract: Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.Type: GrantFiled: June 4, 2008Date of Patent: May 7, 2013Assignee: The Johns Hopkins UniversityInventors: John Martin Abraham, Stephen J. Meltzer
-
Patent number: 8435493Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).Type: GrantFiled: November 15, 2010Date of Patent: May 7, 2013Assignee: Emory UniversityInventor: Mark M. Goodman
-
Publication number: 20130101508Abstract: Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.Type: ApplicationFiled: April 15, 2010Publication date: April 25, 2013Applicant: Lantheus Medical Imaging, Inc.Inventors: James F. Castner, Dianne D. Zdankiewicz, James E. Anderson
-
Patent number: 8420052Abstract: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.Type: GrantFiled: July 24, 2009Date of Patent: April 16, 2013Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Wei Zhang, Umesh B. Gangadharmath, Dhanalakshmi Kasi, Kai Chen, Anjana Sinha, Eric Wang, Gang Chen, Peter J. H. Scott, Henry Clifton Padgett, Qianwa Liang, Zhiyong Gao, Tieming Zhao, Chunfang Xia, Vani P. Mocharla
-
Patent number: 8420049Abstract: Radiolabeled adenosine or radiolabeled adenosine containing molecules for use in positron emission tomography for assessing alterations in adenylate metabolism in a patient are provided.Type: GrantFiled: February 17, 2012Date of Patent: April 16, 2013Inventor: Edward H. Abraham
-
Publication number: 20130084245Abstract: The present invention provides methods of monitoring A?-directed immunotherapy. The methods involve administering a PET ligand that binds to amyloid deposits and detecting the PET ligand in the brain to provide an indication of the level and/or distribution of amyloid deposits. Surprisingly, the data in the present application show that a statistically significant reduction in amyloid deposits occurs early and consistently among patients following initiation of treatment before statistically significant effects of most if not all other markers are detectable. In consequence, the present methods allow early detection of whether a patient is responding to the A?-directed immunotherapy and if necessary adjustment of the immunotherapy regime.Type: ApplicationFiled: February 25, 2011Publication date: April 4, 2013Applicants: Wyeth LLC, Janssen Alzheimer ImmunotherapyInventors: Ronald Black, Michael Grundman
-
Publication number: 20130084244Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.Type: ApplicationFiled: November 21, 2012Publication date: April 4, 2013Applicant: Koninklijke Philips Electronics N.V.Inventor: Koninklijke Philips Electronics N.V.
-
Patent number: 8409547Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C?N+—O???(II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: GrantFiled: June 25, 2012Date of Patent: April 2, 2013Assignee: Hammersmith Imanet LimitedInventors: Matthias Eberhard Glaser, Erik Arstad
-
Patent number: 8404213Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.Type: GrantFiled: December 17, 2010Date of Patent: March 26, 2013Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: William E. Klunk, Chester A. Mathis, Jr., Yanming Wang
-
Patent number: 8398956Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: GrantFiled: December 2, 2011Date of Patent: March 19, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20130064770Abstract: The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.Type: ApplicationFiled: May 26, 2011Publication date: March 14, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Ian Martin Newington, Duncan George Wynn, Robert James Domett Nairne, Benedicte Guilbert, Subrata Mandal, Jinto Jose, Sunderaraman Varadarajan, Chitralekha Rangaswamy, Helen Betts, Rebecca Davis
-
Publication number: 20130058866Abstract: 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: ApplicationFiled: August 29, 2012Publication date: March 7, 2013Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
-
Patent number: 8383083Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.Type: GrantFiled: June 30, 2011Date of Patent: February 26, 2013Assignee: University of Western OntarioInventors: Duncan H. Hunter, Mustafa Janabi
-
Publication number: 20130045164Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.Type: ApplicationFiled: October 23, 2012Publication date: February 21, 2013Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventor: UNIVERSITY OF PITTSBURGH - OF THE COMM
-
Patent number: 8377419Abstract: An imaging agent is disclosed for use in nuclear magnetic resonance imaging. The imaging agent includes a first substance and a second substance. The first substance includes at least one atom having non-zero nuclear spin providing a polarized magnetic orientation. The second substance is bound to the first substance and inhibits physical contact between the at least one atom and other atoms and molecules to thereby inhibit spin relaxation of the polarized magnetic orientation of the at least one atom.Type: GrantFiled: September 28, 2006Date of Patent: February 19, 2013Assignee: The President and Fellows of Harvard CollegeInventor: Charles M. Marcus
-
Patent number: RE44338Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: July 17, 2012Date of Patent: July 2, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
-
Patent number: RE44354Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: July 17, 2012Date of Patent: July 9, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky